A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 305 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence April 29, 2019 Study Suggests a Link between Stress and Cancer Coming Back January 14, 2021 ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ) February 7, 2019 Adagrasib Shows Clinical Efficacy in Patients with Previously Treated KRASG12C-Mutated Advanced... June 9, 2022 Load more HOT NEWS Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia 7 images that defined cancer policy in 2022 Woman, 88, Had Been Waving from Her Window for Over a... FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer
